A study from Karl Landsteiner University of Health Sciences demonstrates that treatment with focused ultrasound (HIFU) effectively controls prostate cancer and maintains patients’ quality of ...

The identification of 20 causal plasma proteins for prostate cancer represents a critical step toward addressing the need for improved diagnostic specificity and reveals promising new targets for ...

ROME — Rome Health is expanding its robotic surgery program to provide men with a new minimally invasive option to treat an ...

And what can you expect during your visit? Two urologists have answers:According to Dr Axel Merseburger, spokesman for the German Society for Urology (DGU), a man should see a urologist in cases of ...

Rome Health is expanding its robotic surgery program to offer a new minimally invasive option for treating an enlarged ...

Halda Therapeutics is developing oral assets for prostate and lung cancer. The deal comes after Johnson & Johnson set an ...

Johnson & Johnson is paying $3.05 billion to acquire Halda Therapeutics, obtaining a novel cell death platform while ...

Halda to be acquired by Johnson & Johnson for $3.05 billion in cashHalda recently presented positive Phase 1/2 data for ...

Dr. Christopher Kelly: A biomarker is a biological substance that can be objectively measured and tracked to provide ...

With rates of advanced prostate cancer on the rise, local medical experts offer advice on screenings, risks, and new ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered ...

"Our exclusive partnership with Profound Medical marks a significant step in advancing precision prostate care across Australia and New Zealand,” commented Getz Healthcare ANZ Managing Director, Derek ...